Indian Hospital Chain To Enter Drug-Making Business By Buying Firm
This article was originally published in PharmAsia News
Executive Summary
India's largest hospital chain plans to get into the pharmaceutical business through an acquisition and into clinical trials in collaboration with foreign companies. Apollo Hospitals sees an opportunity to get into the drugs end of the health care at a time of depressed prices brought on by a bad global economy. Apollo, through a wholly owned subsidiary, already is close to signing joint ventures with two U.S. companies for Phase I and II trials of cancer and heart drugs. The Apollo group also conducts Phase III trials for several companies. (Click here for more
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.